About Agilent Technologies, Inc.
https://www.agilent.comAgilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide.
CEO
Padraig McDonnell
Compensation Summary
(Year 2024)
Salary $869,962
Stock Awards $5,981,631
Incentive Plan Pay $669,309
All Other Compensation $21,314
Total Compensation $9,046,505
Industry Medical - Diagnostics & Research
Sector Healthcare
Went public November 18, 1999
Full time employees 17,900
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2014-11-03 | Forward | 699:500 |
ETFs Holding This Stock
Summary
Total 779
Showing Top 3 of 779
Ratings Snapshot
Rating : B+
Discounted Cash Flow 4
Return On Equity 5
Return On Assets 5
Debt To Equity 2
Price To Earnings 2
Price To Book 1
Overall Score 3
Most Recent Analyst Grades
Grade Summary
Buy 3
Outperform 1
Overweight 3
Market Perform 1
In Line 1
Neutral 1
Hold 1
Showing Top 6 of 11
Price Target
Target High $180
Target Low $130
Target Median $165
Target Consensus $165
Institutional Ownership
VANGUARD GROUP INC
Shares:34.04M
Value:$4.97B
BLACKROCK, INC.
Shares:26.14M
Value:$3.82B
BLACKROCK INC.
Shares:25.26M
Value:$3.69B
Summary
% Of Shares Owned 72.74%
Total Number Of Holders 1,438
Showing Top 3 of 1,438
Market Cap $41.32 B
52w High $160.27
52w Low $96.43
Dividend Yield 0.70%
Frequency Quarterly
P/E 31.93
Volume 1.34M
Outstanding Shares 283.50M
About Agilent Technologies, Inc.
https://www.agilent.comAgilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q4-2025 | $1.86B ▲ | $521M ▼ | $434M ▲ | 23.32% ▲ | $1.53 ▲ | $540M ▲ |
| Q3-2025 | $1.74B ▲ | $554M ▼ | $336M ▲ | 19.33% ▲ | $1.18 ▲ | $466M ▲ |
| Q2-2025 | $1.67B ▼ | $566M ▲ | $215M ▼ | 12.89% ▼ | $0.75 ▼ | $362M ▼ |
| Q1-2025 | $1.68B ▼ | $523M ▲ | $318M ▼ | 18.92% ▼ | $1.12 ▼ | $467M ▼ |
| Q4-2024 | $1.7B | $508M | $351M | 20.63% | $1.23 | $502M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q4-2025 | $1.79B ▲ | $12.73B ▲ | $5.99B ▲ | $6.74B ▲ |
| Q3-2025 | $1.53B ▲ | $12.23B ▲ | $5.86B ▼ | $6.37B ▲ |
| Q2-2025 | $1.49B ▲ | $12.16B ▲ | $6.02B ▲ | $6.14B ▲ |
| Q1-2025 | $1.47B ▲ | $11.91B ▲ | $5.89B ▼ | $6.03B ▲ |
| Q4-2024 | $1.33B | $11.85B | $5.95B | $5.9B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q4-2025 | $434M ▲ | $545M ▲ | $-90M ▲ | $-200M ▲ | $254M ▲ | $452M ▲ |
| Q3-2025 | $336M ▲ | $362M ▲ | $-96M ▲ | $-219M ▼ | $48M ▲ | $259M ▲ |
| Q2-2025 | $215M ▼ | $221M ▼ | $-114M ▼ | $-116M ▲ | $19M ▼ | $107M ▼ |
| Q1-2025 | $318M ▼ | $431M ▼ | $-94M ▲ | $-180M ▼ | $138M ▲ | $334M ▼ |
| Q4-2024 | $351M | $481M | $-954M | $25M | $-450M | $388M |
Revenue by Products
| Product | Q1-2025 | Q2-2025 | Q3-2025 | Q4-2025 |
|---|---|---|---|---|
 Agilent CrossLab | $700.00M ▲ | $710.00M ▲ | $740.00M ▲ | $760.00M ▲ |
 Applied Markets | $340.00M ▲ | $300.00M ▼ | $320.00M ▲ | $350.00M ▲ |
 Life Sciences and Applied Markets | $650.00M ▲ | $650.00M ▲ | $670.00M ▲ | $760.00M ▲ |
Revenue by Geography
| Region | Q4-2025 | Q3-2025 | Q1-2025 | Q2-2025 |
|---|---|---|---|---|
 Americas | $780.00M ▲ | $680.00M ▼ | $670.00M ▼ | $680.00M ▲ |
 Asia Pacific | $560.00M ▲ | $560.00M ▲ | $550.00M ▼ | $550.00M ▲ |
 Europe | $530.00M ▲ | $490.00M ▼ | $460.00M ▼ | $440.00M ▼ |
CEO
Padraig McDonnell
Compensation Summary
(Year 2024)
Salary $869,962
Stock Awards $5,981,631
Incentive Plan Pay $669,309
All Other Compensation $21,314
Total Compensation $9,046,505
Industry Medical - Diagnostics & Research
Sector Healthcare
Went public November 18, 1999
Full time employees 17,900
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2014-11-03 | Forward | 699:500 |
ETFs Holding This Stock
Summary
Total 779
Showing Top 3 of 779
Ratings Snapshot
Rating : B+
Discounted Cash Flow 4
Return On Equity 5
Return On Assets 5
Debt To Equity 2
Price To Earnings 2
Price To Book 1
Overall Score 3
Most Recent Analyst Grades
Grade Summary
Buy 3
Outperform 1
Overweight 3
Market Perform 1
In Line 1
Neutral 1
Hold 1
Showing Top 6 of 11
Price Target
Target High $180
Target Low $130
Target Median $165
Target Consensus $165
Institutional Ownership
VANGUARD GROUP INC
Shares:34.04M
Value:$4.97B
BLACKROCK, INC.
Shares:26.14M
Value:$3.82B
BLACKROCK INC.
Shares:25.26M
Value:$3.69B
Summary
% Of Shares Owned 72.74%
Total Number Of Holders 1,438
Showing Top 3 of 1,438